Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending May 23, 2016. The report serves as a notification of transactions involving directors, persons discharging managerial responsibilities, or connected persons, in accordance with DTR 3.1.4 R(1)(c).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of specific insider transactions rather than a financial performance report.
Material Changes
The filing discloses an increase in the notional allocation of GSK American Depositary Shares (ADSs) on May 20, 2016. This change resulted from the revaluation of the cash element of a notional investment held within the GSK 401(K) plan. The transaction occurred at a price of $42.01 per ADS.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Investor Verification Points
- Verify the specific details of the notional investment revaluation within the GSK 401(K) plan.
- Confirm the identity of the connected person involved: Dr K Slaoui (Connected Person of Dr M M Slaoui).
- Note the transaction volume: 7 ADSs.
- Confirm the transaction price: $42.01 per ADS.
- Review the full 401(K) plan disclosures for broader context on employee holdings.